Literature DB >> 20433428

The metabolic syndrome in patients on peritoneal dialysis: prevalence and influence on cardiovascular morbidity.

Senija Rasić1, Almira Hadzović-Dzuvo, Damir Rebić, Snezana Uncanin, Azra Hadzić, Aida Mujaković, Indira Kulenović.   

Abstract

The metabolic syndrome (MS) is a multi-factorial disorder which includes a main risk factors associated with the development of cardiovascular, neurologic, renal and endocrine diseases, especially type 2 diabetes. This study has been conducted to estimate the prevalence of the MS in patients undergoing continuous ambulatory peritoneal dialysis (CAPD) and its association with cardiovascular morbidity. The study included 37 patients (25 type 2 diabetic patients and 12 non-diabetic patients), who had been on peritoneal dialysis for > 3 months. At the beginning of CAPD treatment (baseline) and at the end of follow-up, we measured: body mass index (BMI), blood pressure, fasting blood glucose, triglycerides and high-density lipoprotein cholesterol (HDLC) and defined the prevalence of the MS using the modified National Cholesterol Education Program (NCEP; Adult Treatment Panel III) for peritoneal dialysis patients. The overall prevalence of the MS was 89.2%. The metabolic syndrome was estimated in all (100%) type 2 diabetic patients (vs. 60% patients on the beginning of CAPD treatment). In non-diabetic peritoneal patients, the MS was estimated in 50% cases, according to 33.3% at the beginning CAPD treatment. Development of the MS was significantly higher in the type 2 diabetic patients in compared with non-diabetic patients until the end of follow-up examination (p=0.0005). The prevalence of LVH in type 2 diabetic patients with the MS was significantly higher (p=0.002) than in non-diabetic peritoneal patients with the MS. We didn't found statistical significantly difference in the prevalence of ischemic heart disease between this two category of peritoneal dialysis patients (p=0.076). The results indicate that the metabolic syndrome is presented in high percentage in peritoneal dialysis patients, and it's also important risk factor of high cardiovascular morbidity rate in these patients, especially in type 2 diabetic patients.

Entities:  

Mesh:

Year:  2010        PMID: 20433428      PMCID: PMC5627710          DOI: 10.17305/bjbms.2010.2638

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  16 in total

Review 1.  Metabolic effects of continuous ambulatory peritoneal dialysis.

Authors:  G Morrison
Journal:  Annu Rev Med       Date:  1989       Impact factor: 13.739

2.  Prevalence of the metabolic syndrome in an incident dialysis population.

Authors:  Daniel O Young; Richard J Lund; Gleb Haynatzki; Robert W Dunlay
Journal:  Hemodial Int       Date:  2007-01       Impact factor: 1.812

Review 3.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

Review 4.  Strategies to reduce glucose exposure in peritoneal dialysis patients.

Authors:  C J Holmes; T R Shockley
Journal:  Perit Dial Int       Date:  2000       Impact factor: 1.756

5.  Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study.

Authors:  Jacqueline M Dekker; Cynthia Girman; Thomas Rhodes; Giel Nijpels; Coen D A Stehouwer; Lex M Bouter; Robert J Heine
Journal:  Circulation       Date:  2005-08-02       Impact factor: 29.690

Review 6.  Metabolic syndrome, cardiovascular risk and screening for subclinical atherosclerosis.

Authors:  Shaista Malik; Nathan D Wong
Journal:  Expert Rev Cardiovasc Ther       Date:  2009-03

7.  Prevalence and correlates of left ventricular hypertrophy in the African American Study of Kidney Disease Cohort Study.

Authors:  Gail E Peterson; Tine de Backer; Avril Gabriel; Vladimir Ilic; Tudor Vagaonescu; Lawrence J Appel; Gabriel Contreras; Cindy Kendrick; Stephen Rostand; Robert A Phillips
Journal:  Hypertension       Date:  2007-10-29       Impact factor: 10.190

Review 8.  Metabolic syndrome pandemic.

Authors:  Scott M Grundy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-03       Impact factor: 8.311

9.  Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study).

Authors:  Marcello Chinali; Richard B Devereux; Barbara V Howard; Mary J Roman; Jonathan N Bella; Jennifer E Liu; Helaine E Resnick; Elisa T Lee; Lyle G Best; Giovanni de Simone
Journal:  Am J Cardiol       Date:  2004-01-01       Impact factor: 2.778

Review 10.  Metabolic syndrome: maladaptation to a modern world.

Authors:  Terence J Wilkin; Linda D Voss
Journal:  J R Soc Med       Date:  2004-11       Impact factor: 18.000

View more
  2 in total

1.  Metabolic syndrome in peritoneal dialysis patients: choice of diagnostic criteria and prognostic implications.

Authors:  Cheuk-Chun Szeto; Bonnie Ching-Ha Kwan; Kai-Ming Chow; Chi-Bon Leung; Mei-Shan Cheng; Man-Ching Law; Philip Kam-Tao Li
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

2.  High glucose concentrations in peritoneal dialysate are associated with all-cause and cardiovascular disease mortality in continuous ambulatory peritoneal dialysis patients.

Authors:  Yueqiang Wen; Qunying Guo; Xiao Yang; Xianfeng Wu; Shaozhen Feng; Jiaqing Tan; Ricong Xu; Xueqing Yu
Journal:  Perit Dial Int       Date:  2013-12-01       Impact factor: 1.756

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.